[1]成若晨,张 璎,何腾飞,等.原卟啉Ⅸ在HBV相关肝硬化中的临床意义[J].医学信息,2021,34(06):73-77.[doi:10.3969/j.issn.1006-1959.2021.06.019]
　CHENG Ruo-chen,ZHANG Ying,HE Teng-fei,et al.The Clinical Significance of Protoporphyrin Ⅸ in HBV-related Liver Cirrhosis[J].Medical Information,2021,34(06):73-77.[doi:10.3969/j.issn.1006-1959.2021.06.019]
点击复制

原卟啉Ⅸ在HBV相关肝硬化中的临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年06期
页码:
73-77
栏目:
论著
出版日期:
2021-03-15

文章信息/Info

Title:
The Clinical Significance of Protoporphyrin Ⅸ in HBV-related Liver Cirrhosis
文章编号:
1006-1959（2021）06-0073-05
作者:
成若晨; 张 璎; 何腾飞; 等
（西安医学院临床医学院，陕西 西安 710021）
Author(s):
CHENG Ruo-chen; ZHANG Ying; HE Teng-fei; et al.
(Clinical School,Xi’an Medical University,Xi’an 710021,Shaanxi,China)
关键词:
乙型病毒性肝炎; 肝硬化; 原卟啉Ⅸ
Keywords:
Viral hepatitis B; Liver cirrhosis; Protoporphyrin Ⅸ
分类号:
R575
DOI:
10.3969/j.issn.1006-1959.2021.06.019
文献标志码:
A
摘要:
目的 探讨原卟啉Ⅸ（PPⅨ）在乙型肝炎病毒（HBV）相关肝硬化患者肝功能及抗病毒疗效评估中的临床意义。方法 选择2018年10月~2019年10月就诊于西安医学院第一附属医院的51例HBV相关肝硬化患者作为肝硬化组，另选同期本院40名健康人群作为对照组；采用高效液相色谱法（HPLC）检测两组血清PPⅨ水平，分析PPⅨ与常规实验室指标对肝功能、抗病毒治疗效果的评估价值。结果 肝硬化组PPⅨ水平高于对照组，且肝硬化组Child-Pugh A、B、C 各级患者PPⅨ水平均高于对照组，差异有统计学意义（P＜0.05）；肝硬化组Child-Pugh A级患者PPⅨ水平高于B、C 级，差异有统计学意义（P＜0.05），而Child-Pugh B、C级患者PPⅨ水平比较，差异无统计学意义（P＞0.05）；PPⅨ与Child-Pugh评分、APRI评分、FIB-4评分、TBIL、AST、ALT、ALB、PLT、PT 均呈正相关（P＜0.05），与HBV-DNA、ALP、GGT 无相关性（P＞0.05）；ROC曲线显示，Child-Pugh＞7分时，PPⅨ评估Child-Pugh评分的曲线下面积（AUC）为 0.853，临界值 62.05 ng/dl，灵敏度86.20%，特异度 75.00%，95%CI：0.781~0.952；肝硬化组治疗前、治疗12、24周后，患者血清PPⅨ、TBIL水平依次降低，差异有统计学意义（P＜0.05），HBV-DNA、AST、ALT、ALB、PT水平与治疗前比较，差异有统计学意义（P＜0.05），治疗前后PLT、ALP、GGT水平比较，差异无统计学意义（P＞0.05）。结论 肝硬化患者原卟啉Ⅸ水平高于健康人群，该指标可作为评估乙肝肝硬化患者肝功能损害的预警因子，也可用于抗HBV治疗效果的评估。
Abstract:
Objective To explore the clinical significance of protoporphyrin Ⅸ (PPⅨ) in the evaluation of liver function and antiviral efficacy in patients with hepatitis B virus (HBV)-related cirrhosis.Methods 51 patients with HBV-related cirrhosis who were admitted to the First Affiliated Hospital of Xi’an Medical University from October 2018 to October 2019 were selected as the cirrhosis group, and 40 healthy people in the hospital during the same period were selected as the control group;High performance liquid chromatography (HPLC) was used to detect the levels of serum PPⅨ in the two groups, and the evaluation value of PPⅨ and routine laboratory indicators on liver function and antiviral treatment effects were analyzed.Results Before treatment, the PPⅨ level of the cirrhosis group was higher than that of the control group, and the PPⅨ level of Child-Pugh A, B, C patients in the liver cirrhosis group was higher than that of the control group, the difference was statistically significant (P<0.05);The PPⅨ level of Child-Pugh A patients in the liver cirrhosis group was higher than that of B and C,the difference was statistically significant (P＜0.05).However, there was no statistically significant difference in the PPⅨ level of Child-Pugh B and C patients (P>0.05);PPⅨ was positively correlated with Child-Pugh score, APRI score, FIB-4 score, TBIL, AST, ALT, ALB, PLT, PT (P<0.05),no correlation with HBV-DNA, ALP, GGT (P>0.05);The ROC curve showed that when Child-Pugh>7 points, the area under the curve (AUC) for PPIX assessment of Child-Pugh score was 0.853, the cut-off value was 62.05 ng/dl, the sensitivity was 86.20%, the specificity was 75.00%, and the 95% CI: 0.781~ 0.952; before treatment and after 12 and 24 weeks of treatment in the liver cirrhosis group, the serum levels of PPⅨ and TBIL decreased successively,the difference was statistically significant (P<0.05).HBV-DNA, AST, ALT, ALB, PT levels were compared with those before treatment, the difference was statistically significant (P<0.05),There was no statistically significant difference in the levels of PLT, ALP, and GGT before and after treatment (P>0.05).Conclusion The level of protoporphyrin IX in patients with liver cirrhosis is higher than that in healthy people. This indicator can be used as an early warning factor for evaluating liver damage in patients with hepatitis B cirrhosis, and it can also be used to evaluate the effect of anti-HBV treatment.

参考文献/References:

[1]王贵强,王福生,庄辉,等.慢性乙型肝炎防治指南（2019年版)[J].临床肝胆病杂志,2019,35(12):2648-2669. [2]Mansouri A,Gattolliat C,Asselah T.Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases[J].Gastroenterology,2018,155(3):629-647. [3]Ogun AS,Valentine M.Biochemistry,Heme Synthesis[M].Treasure Island:StatPearls Publishing,2020. [4]鲍婕.异烟肼和利福平联用致原卟啉IX积聚造成肝损伤的机制研究[D].安徽医科大学,2018. [5]Sachar M,Anderson KE,Ma X.Protoporphyrin Ⅸ:the Good,the Bad,and the Ugly[J].J Pharmacol Exp Ther,2016,356(2):267-275. [6]Takafumi N,Kyoji M,Kazuhiko K,et al.Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells[J].PLoS One,2018,13(6):e0198345. [7]陈洋,李晓青.《2017年美国推进转化科学中心罕见疾病临床研究网络卟啉病联合会:急性肝卟啉病的评估和长期管理建议》摘译[J].临床肝胆病杂志,2017,33(11):2083-2086. [8]Harvinder S.Loss of hepatocyte β-catenin protects mice from experimental porphyria-associated liver injury[J].Journal of Hepatology,2019,1(70):108-117. [9]Sastre L,To-Figueras J,Lens S,et al.Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct‐acting anti‐virals[J].Alimentary Pharmacology&Therapeutics,2020,51(10):968-973. [10]Mansouri A,Gattolliat C,Asselah T.Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases[J].Gastroenterology,2018,155(3):629-647. [11]朱芳成,毕华强,赵毅,等.乙型肝炎病毒核心蛋白触发人肝癌细胞异常卟啉代谢的机制[J].病毒学报,2019,35(4):592-598.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Medical Information,2018,31(06):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]邬 剑,李慧玲.ELISA法和胶体金试纸条法在乙肝表面抗原 检测中的应用研究[J].医学信息,2018,31(09):155.[doi:10.3969/j.issn.1006-1959.2018.09.050]
　WU Jian,LI Hui-ling.Application of ELISA and Colloidal Gold Strip in the Detection of Hepatitis B Surface Antigen[J].Medical Information,2018,31(06):155.[doi:10.3969/j.issn.1006-1959.2018.09.050]
[4]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Medical Information,2022,35(06):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[5]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Medical Information,2019,32(06):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[6]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Medical Information,2018,31(06):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[7]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Medical Information,2018,31(06):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[8]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(06):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[9]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Medical Information,2022,35(06):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[10]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,32(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
　MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Medical Information,2019,32(06):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
[11]刘 芳,季 良,姜海燕,等.肝爽颗粒联合富马酸替诺福韦二吡呋酯片对乙型病毒性肝炎肝硬化患者APRI、FIB-4的影响[J].医学信息,2021,34(05):104.[doi:10.3969/j.issn.1006-1959.2021.05.029]
　LIU Fang,JI Liang,JIANG Hai-yan,et al.The Effect of Ganshuang Granule Combined with Tenofovir Disoproxil Fumarate Tablets on APRI and FIB-4 in Patients with Hepatitis B Liver Cirrhosis[J].Medical Information,2021,34(06):104.[doi:10.3969/j.issn.1006-1959.2021.05.029]
[12]王露露.2019-2021年锦州乙型病毒性肝炎的流行病学特征[J].医学信息,2021,34(24):128.[doi:10.3969/j.issn.1006-1959.2021.24.032]
　WANG Lu-lu.Epidemiological Characteristics of Viral Hepatitis B in Jinzhou from 2019 to 2021[J].Medical Information,2021,34(06):128.[doi:10.3969/j.issn.1006-1959.2021.24.032]

更新日期/Last Update: 1900-01-01